Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGN-2009 and Pembrolizumab in Recurrent or Metastatic Cervical Cancer
NCT06157151Phase 2Recruiting
- Sponsor
- Precigen
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PRGN-2009 in Cervical Cancer (CC), sponsored by Precigen. Started Nov 2025; status: recruiting.
02
Drugs
PRGN-2009
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06157151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157151.